Karyopharm receives Grant to further Develop Selective Inhibitors of Nuclear Export Compounds

 – January 9, 2014  –– 

Karyopharm Therapeutics, a clinical-stage pharmaceutical company has been awarded a grant from the National Multiple Sclerosis (MS) Society through its affiliate, Fast Forward, to support research on the potential of SINE compounds in inflammatory models of disease, including MS. The company noted that it is excited about its continuing collaboration with the National MS Society, and with The Mount Sinai Hospital and Patrizia Casaccia, MD, Professor of Neuroscience and Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, who has dedicated herself to advancing research in MS and other important diseases.

-Dr. Patrizia Casaccia, Professor, Neuroscience, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai

Learn more